Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.

    Ota T, Aihara M, Saeki T, Narumiya S, Araie M.

    Br J Ophthalmol. 2007 May;91(5):673-6. Epub 2006 Nov 23.PMID: 17124244 [PubMed - indexed for MEDLINE]Related articles

    2.

    The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.

    Ota T, Aihara M, Narumiya S, Araie M.

    Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63.PMID: 16249494 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice.

    Ota T, Aihara M, Saeki T, Narumiya S, Araie M.

    Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3395-9.PMID: 16877408 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.

    Ota T, Murata H, Sugimoto E, Aihara M, Araie M.

    Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2006-11.PMID: 15914616 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

    Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H.

    Exp Eye Res. 2004 Apr;78(4):767-76.PMID: 15037111 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of prostanoid EP agonists on mouse intraocular pressure.

    Saeki T, Ota T, Aihara M, Araie M.

    Invest Ophthalmol Vis Sci. 2009 May;50(5):2201-8. Epub 2008 Dec 30.PMID: 19117925 [PubMed - indexed for MEDLINE]Related articles

    7.

    A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.

    Sutton A, Gilvarry A, Ropo A.

    J Ocul Pharmacol Ther. 2007 Aug;23(4):359-65.PMID: 17803434 [PubMed - indexed for MEDLINE]Related articles

    8.

    Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.

    Sutton A, Gouws P, Ropo A.

    Int J Clin Pharmacol Ther. 2008 Aug;46(8):400-6.PMID: 18793581 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice.

    Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN.

    Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4571-7.PMID: 16303950 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Ocular hypotensive effects of anti-glaucoma agents in mice.

    Akaishi T, Odani-Kawabata N, Ishida N, Nakamura M.

    J Ocul Pharmacol Ther. 2009 Oct;25(5):401-8.PMID: 19857101 [PubMed - in process]Related articles

    11.

    Short-term effects of topical tafluprost on retinal blood flow in cats.

    Izumi N, Nagaoka T, Sato E, Mori F, Takahashi A, Sogawa K, Yoshida A.

    J Ocul Pharmacol Ther. 2008 Oct;24(5):521-6.PMID: 18808364 [PubMed - indexed for MEDLINE]Related articles

    12.

    Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.

    Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL.

    J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.PMID: 19232013 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor.

    Crowston JG, Lindsey JD, Aihara M, Weinreb RN.

    Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3555-9.PMID: 15452062 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    [Receptors involved in the mechanism of action of topical prostaglandines]

    Neacsu AM.

    Oftalmologia. 2009;53(2):3-7. Review. Romanian. PMID: 19697832 [PubMed - indexed for MEDLINE]Related articles

    15.

    The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.

    Nilsson SF, Drecoll E, Lütjen-Drecoll E, Toris CB, Krauss AH, Kharlamb A, Nieves A, Guerra T, Woodward DF.

    Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4042-9.PMID: 16936121 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.

    Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, Hara H.

    Biol Pharm Bull. 2003 Dec;26(12):1691-5.PMID: 14646172 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Prostaglandin FP receptors do not contribute to 24-hour intraocular pressure variation in mice.

    Crowston JG, Morris CA, Lindsey JD, Weinreb RN.

    Invest Ophthalmol Vis Sci. 2007 May;48(5):2095-8.PMID: 17460266 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effects of prostaglandin F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and contraction in cat iris sphincter.

    Ansari HR, Davis AM, Kaddour-Djebbar I, Abdel-Latif AA.

    J Ocul Pharmacol Ther. 2003 Jun;19(3):217-31.PMID: 12828840 [PubMed - indexed for MEDLINE]Related articles

    19.

    Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists.

    Bhattacherjee P, Williams BS, Paterson CA.

    Invest Ophthalmol Vis Sci. 1999 Nov;40(12):3047-53.PMID: 10549672 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes.

    Serle JB, Wang RF, Mittag TW, Shen F, Podos SM.

    J Glaucoma. 2001 Jun;10(3):215-9.PMID: 11442186 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data